Paper36563
Cyclophosphamide therapy of severe systemic necrotizing vasculitis.
Fauci AS and 3 others. N Engl J Med, 1979. Cited by 538 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Cyclophosphamide therapy of severe systemic necrotizing vasculitis. Papers, record 36563. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36563
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cyclophosphamide | Major topic |
| Polyarteritis Nodosa | Major topic |
| Vasculitis | Major topic |
| Adolescent | |
| Adrenal Cortex Hormones | |
| Adult | |
| Azathioprine | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Necrosis | |
| Recurrence | |
| Remission, Spontaneous | |
| Syndrome | |
| Time Factors |
Source PubMed
Cited by84
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 538 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42383040 | Hypogammaglobulinaemia in patients with ANCA-associated vasculitis treated with rituximab. | Front Med (Lausanne) | 2026 | https://conductscience.org/library/papers/42383040 | PubMed |
| 41052893 | Efficacy and safety of avacopan for treatment of patients with ANCA-associated vasculitis receiving cyclophosphamide. | RMD Open | 2025 | https://conductscience.org/library/papers/41052893 | PubMed |
| 40250881 | Myocardial infarction in ANCA-associated vasculitis: a population-based cohort study. | RMD Open | 2025 | https://conductscience.org/library/papers/40250881 | PubMed |
| 39969779 | The Expanding Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Armamentarium. | Drugs | 2025 | https://conductscience.org/library/papers/39969779 | PubMed |
| 39077977 | Treatment of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis With Diffuse Alveolar Hemorrhage With Avacopan. | ACR Open Rheumatol | 2024 | https://conductscience.org/library/papers/39077977 | PubMed |
| 39036255 | Rheumatoid Vasculitis in Modern Era: A Case Report and Comprehensive Literature Review. | Cureus | 2024 | https://conductscience.org/library/papers/39036255 | PubMed |
| 38913291 | Classification Criteria for ANCA Associated Vasculitis - Ready for Prime Time? | Curr Rheumatol Rep | 2024 | https://conductscience.org/library/papers/38913291 | PubMed |
| 38558645 | A Rare Presentation of Polyarteritis Nodosa (PAN). | Cureus | 2024 | https://conductscience.org/library/papers/38558645 | PubMed |
| 37979959 | Efficacy and safety of avacopan in patients with ANCA-associated vasculitis receiving rituximab in a randomised trial. | Ann Rheum Dis | 2024 | https://conductscience.org/library/papers/37979959 | PubMed |
| 37947275 | ANCA-associated vasculitis-treatment standard. | Nephrol Dial Transplant | 2024 | https://conductscience.org/library/papers/37947275 | PubMed |
| 37547534 | Outcomes in ANCA-Associated Vasculitis in Scotland: Validation of the Renal Risk Score in a Complete National Cohort. | Kidney Int Rep | 2023 | https://conductscience.org/library/papers/37547534 | PubMed |
| 36505909 | Caecal Ameboma, colorectal malignancy mimicker in young male with ANCA-associated vasculitis. | IDCases | 2023 | https://conductscience.org/library/papers/36505909 | PubMed |
| 36244021 | Predictors of poor prognosis in ANCA-associated vasculitis (AAV): a single-center prospective study of inpatients in China. | Clin Exp Med | 2023 | https://conductscience.org/library/papers/36244021 | PubMed |
| 33909172 | Novel Therapies for ANCA-associated Vasculitis. | Curr Rheumatol Rep | 2021 | https://conductscience.org/library/papers/33909172 | PubMed |
| 33512781 | Polyarteritis Nodosa: A Systematic Review of Test Accuracy and Benefits and Harms of Common Treatments. | ACR Open Rheumatol | 2021 | https://conductscience.org/library/papers/33512781 | PubMed |
| 33372616 | French recommendations for the management of systemic necrotizing vasculitides (polyarteritis nodosa and ANCA-associated vasculitides). | Orphanet J Rare Dis | 2020 | https://conductscience.org/library/papers/33372616 | PubMed |
| 32833085 | Certain perspectives about the use of corticosteroids for managing hospitalized patients with rheumatic diseases. | Clin Rheumatol | 2020 | https://conductscience.org/library/papers/32833085 | PubMed |
| 31242923 | Hallmark trials in ANCA-associated vasculitis (AAV) for the pediatric rheumatologist. | Pediatr Rheumatol Online J | 2019 | https://conductscience.org/library/papers/31242923 | PubMed |
| 30413153 | Early predictors of one-year mortality in patients over 65 presenting with ANCA-associated renal vasculitis: a retrospective, multicentre study. | BMC Nephrol | 2018 | https://conductscience.org/library/papers/30413153 | PubMed |
| 29971584 | Oral cyclophosphamide in treatment of patients with refractory idiopathic inflammatory myopathies: a retrospective observational study. | Clin Rheumatol | 2018 | https://conductscience.org/library/papers/29971584 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36563
GET https://conductscience.org/api/papers/v1/36563/cited_by?page=2